We embrace collaboration over competition to drive innovation in drug development and healthcare

Our partners leverage Concr advanced predictive modelling across every stage of therapeutic development to create shared value for the benefit of cancer patients.

Who do we partner with?

Concr partnerships are typically shaped around a specific question. We collaborate with:

  • Pharmaceutical companies
  • Biotechnology companies
  • Diagnostics companies
  • R&D institutions
  • Healthcare providers
  • Public bodies

Minimal data input

Meaningful and actionable biomarker predictions using 300x less pre-clinical and 7x less clinical data

Focus on early-phase trials

Identify responders at the earliest stage of clinical drug development, mitigating risk of failure

Broad biological intelligence

Single analytical project can generate a wealth of clinically-actionable predictions, including new assets

Proven technology

10+ years of astrophysics research used to model tumour complexity and predict causes of its evolution

Our partners

our deck

FarrSight® demo

Tell us about yourself

Tell us about yourself

Check your inbox

Thank you for providing your details. Please check you inbox for where you should have received an email with a download link to our one-pager.

Thank you for your interest

We have received your details. A member of the Concr team will be in touch soon.

Get in touch

If you’d like more information or have an enquiry, please contact us.

Please send your enquiry to:

Your message has been sent

Thank you for contacting us, a member of the Concr team will be in touch to discuss your enquiry.